Striatal miR-183-5p inhibits methamphetamine-induced locomotion by regulating glucocorticoid receptor signaling. 2022

Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
College of Pharmacy, Keimyung University, Daegu, South Korea.

MicroRNA (miRNA)-mediated striatal gene regulation may play an important role in methamphetamine (METH) addiction. This study aimed to identify changes in novel miRNAs and their target genes during METH self-administration and investigate their roles in METH-induced locomotion. RNA sequencing analysis revealed that mir-183-5p was upregulated in the striatum of METH self-administered rats, and target gene prediction revealed that the glucocorticoid receptor (GR) gene, Nr3c1, was a potential target gene for mir-183-5p. We confirmed that single and repeated METH administrations increased METH-induced locomotion and plasma corticosterone levels in rats. Additionally, increased miR-185-5p expression and decreased GR gene expression were observed only in the repeated-METH-injection group but not in the single-injection group. We then investigated the effects of miR-183-5p on METH-induced locomotion using a miR-183-5p mimic and inhibitor. Injection of a mir-183-5p mimic in the striatum of rats attenuated METH-induced locomotion, whereas injection of a miR-183-5p inhibitor enhanced the locomotor activity in METH-administered rats. Furthermore, the miR-183-5p mimic reduced the phosphorylation of tyrosine hydroxylase (TH) whereas the inhibitor increased it. Taken together, these results indicate that repeated METH injections increase striatal miR-183-5p expression and regulate METH-induced locomotion by regulating GR expression in rats, thereby suggesting a potential role of miR-183-5p as a novel regulator of METH-induced locomotion.

UI MeSH Term Description Entries

Related Publications

Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
January 2020, Frontiers in pharmacology,
Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
November 2020, Molecular medicine reports,
Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
February 2018, Biochemical and biophysical research communications,
Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
February 2020, Cancer medicine,
Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
March 2022, International journal of molecular sciences,
Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
October 2018, International journal of molecular medicine,
Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
October 2019, European review for medical and pharmacological sciences,
Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
January 2022, Journal of oncology,
Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
March 2019, Cell biology international,
Sang-Hoon Song, and Won-Jun Jang, and Eun Young Jang, and Oc-Hee Kim, and Haesoo Kim, and Taekwon Son, and Dong-Young Choi, and Sooyeun Lee, and Chul-Ho Jeong
January 2020, OncoTargets and therapy,
Copied contents to your clipboard!